Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

154 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-30

Study Completion Date

2023-05-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to demonstrate the safety and duration of effect of 40 Units of prabotulinumtoxinA-xvfs (Jeuveau®) in providing temporary improvement in the appearance of moderate to severe glabellar lines (frown lines, which are the vertical lines that develop between the eyebrows) in adult participants. It will also determine if the duration of effect of 40 Units of Jeuveau® is greater than that of 20 Units of Jeuveau® and 20 Units of Botox® Cosmetic.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Jeuveau Treatment of Glabellar Lines Using OLD Versus COLD

NCT05129319

Glabellar Frown Lines

COMPLETED EARLY_PHASE1

The Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines

NCT05364580

Glabellar Frown Lines

COMPLETED PHASE3

Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture

NCT06604832

Skin Aging Skin Wrinkling

COMPLETED PHASE1

The Efficacy and Safety of Protoxin in Subjects With Moderate to Severe Glabellar Lines

NCT06124794

Glabellar Frown Lines

COMPLETED PHASE3

A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)

NCT06834789

Glabellar Lines

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicenter, prospective, randomized, double-blind, active-controlled, single-treatment, increasing dose design. Up to one hundred and fifty subjects will be randomized 1:1:1, to either 20 Units onabotulinumtoxinA (Botox® Cosmetic), 20 Units prabotulinumtoxinA-xvfs (Jeuveau®), or 40 Units prabotulinumtoxinA-xvfs (Jeuveau®).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glabellar Frown Lines

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study Drug

40U of PrabotulinumtoxinA-xvfs

Group Type EXPERIMENTAL

PrabotulinumtoxinA-Xvfs

Intervention Type DRUG

One treatment of 40 units

OnabotulinumtoxinA

20U of OnabotulinumtoxinA

Group Type ACTIVE_COMPARATOR

OnabotulinumtoxinA

Intervention Type DRUG

One treatment of 20 units

PrabotulinumtoxinA-xvfs

20U of PrabotulinumtoxinA-xvfs

Group Type ACTIVE_COMPARATOR

PrabotulinumtoxinA-Xvfs

Intervention Type DRUG

One treatment of 20 units

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PrabotulinumtoxinA-Xvfs

One treatment of 40 units

Intervention Type DRUG

OnabotulinumtoxinA

One treatment of 20 units

Intervention Type DRUG

PrabotulinumtoxinA-Xvfs

One treatment of 20 units

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Jeuveau Botox Cosmetic Jeuveau

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Outpatient, male or female of any race, 18 years of age or older.
* Female subjects of childbearing potential must have a negative urine pregnancy test during Visits 1 (Screening) and Visit 2 (if applicable) and practice a reliable method of contraception for the duration of the study.
* Moderate to severe glabellar lines (i.e., score of 2 or 3) on maximum frown as assessed by the investigator using the Glabellar Line Scale (GLS).
* Subject has moderate to severe glabellar lines (i.e., score of 2 or 3) at maximum frown as assessed by the subject using the GLS.
* Able to follow study instructions and likely to complete all required visits.
* Sign the Institutional Review Board (IRB) -approved Informed Consent Form (ICF) prior to any study-related procedures being performed.

Exclusion Criteria

* Female subjects who are pregnant, breast-feeding, or of childbearing potential and not practicing reliable birth control.
* Known hypersensitivity or previous allergic reaction to any constituent of the Investigational Product (IP) or control.
* Any active infection in the area of the injection sites.
* Inability to substantially lessen glabellar frown lines even by physically spreading them apart.
* Marked facial asymmetry (Investigator discretion).
* Ptosis of eyelid and/or eyebrow, or history of eyelid and/or eyebrow ptosis.
* History of facial nerve palsy.
* Excessive dermatochalasis, deep dermal scarring, thick sebaceous skin (Investigator discretion).
* Medical condition that may affect neuromuscular function (e.g., myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis).
* Previous treatment with botulinum toxin of any serotype above the level of the lateral canthus within the last 6 months.
* Planned treatment with botulinum toxin of any serotype below the level of the lateral canthus during the study period.
* Previous treatment with any facial aesthetic procedure (e.g., injection with biodegradable fillers, chemical peeling, photo rejuvenation) in the glabellar area within the last 12 months.
* Previous insertion of permanent material in the glabellar area.
* Any previous energy based or cryotherapy-based treatment of facial muscles superior to the lateral canthus.
* Any other planned facial aesthetic procedure during the trial period, superior to the level of the lateral canthus (can continue with their usual skin care routine).
* Any surgery in the glabellar area including surgical removal of the corrugator, procerus, or depressor supercilii muscles, or a combination of these, or scars in the glabellar area and the surrounding areas (including eyebrow).
* Medical or psychiatric conditions that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study.
* Evidence of recent alcohol or drug abuse (Investigator discretion).
* History of poor cooperation or unreliability.
* Planning to move out of the area prior to study completion.
* Subjects who are investigational site staff members or family members of such employees.
* Exposure to any other investigational drug/device within 30 days prior to Visit 1.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes